
Ollin Biosciences to Be Acquired, Supporting the Development of Innovative Treatments for Vision-Threatening Eye Diseases
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a privately held clinical-stage biopharmaceutical company focused on developing innovative treatments for serious eye diseases. The proposed acquisition includes an upfront payment of $2.2 billion, with the potential for approximately $1.1 billion in additional regulatory and commercial milestone payments, bringing the total potential transaction value to approximately $3.3 billion.
The acquisition represents a significant development in the ophthalmology sector, particularly in the treatment of retinal diseases that can lead to severe vision impairment and blindness. Through the proposed transaction, Johnson & Johnson aims to strengthen its presence in the ophthalmology market and gain access to Ollin’s lead investigational candidate, OLN324, a next-generation bispecific antibody currently in Phase 3 clinical development.
OLN324 is being investigated as a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), two major retinal conditions that affect millions of people worldwide. Both diseases are associated with progressive damage to the retina and can significantly affect patients’ vision and quality of life. The investigational therapy is designed to target two important biological pathways involved in retinal disease progression: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).
The proposed acquisition is expected to provide OLN324 with the opportunity to benefit from Johnson & Johnson’s global development, regulatory, manufacturing and commercial capabilities. By combining Ollin’s clinical-stage ophthalmology research with Johnson & Johnson’s established pharmaceutical infrastructure, the companies aim to further advance the development of innovative treatment options for patients with vision-threatening retinal diseases.
Ollin Biosciences Focuses on Next-Generation Ophthalmology Treatments
Founded in 2023, Ollin Biosciences was established with the objective of identifying, acquiring and accelerating the development of next-generation therapies for serious ophthalmic conditions. Since its formation, the company has focused on advancing innovative treatment approaches intended to improve clinical outcomes for patients affected by diseases that threaten their vision.
Ollin was built around a strategy of bringing together experienced scientific, clinical and business leaders with the financial resources required to advance promising ophthalmology programs through clinical development. Its approach emphasizes identifying therapies with the potential to address important unmet medical needs and accelerating their progression through well-planned development programs.
The company’s lead development program, OLN324, is a bispecific antibody designed to simultaneously inhibit VEGF and Ang2. The candidate has been engineered with optimized molecular size and potency, with the objective of delivering improved therapeutic activity against the biological mechanisms responsible for retinal vascular disease.
The advancement of OLN324 into Phase 3 clinical development represents an important milestone for the relatively young biotechnology company. Its clinical progress has positioned Ollin as a potential contributor to the development of new treatments for wet AMD and diabetic macular edema.
The proposed acquisition by Johnson & Johnson could provide additional resources and operational capabilities to support the continued development of OLN324, including its progression through late-stage clinical evaluation and potential future regulatory submissions.
OLN324 Targets Two Important Pathways in Retinal Diseases
OLN324 is the central asset in Ollin’s development portfolio and is being investigated for two significant retinal disorders: wet age-related macular degeneration and diabetic macular edema.
Wet AMD is a progressive eye disease characterized by the abnormal growth of blood vessels beneath the retina. These blood vessels can leak fluid and blood, resulting in retinal damage and deterioration of central vision. The condition can make everyday activities, including reading, recognizing faces and driving, increasingly difficult.
Diabetic macular edema is a vision-threatening complication of diabetes that develops when fluid accumulates in the macula, the central portion of the retina responsible for detailed vision. Damage to retinal blood vessels can increase vascular leakage, resulting in swelling and impaired visual function. DME remains an important cause of vision loss among people living with diabetes.
Together, wet AMD and diabetic macular edema affect more than 40 million people worldwide, representing a substantial global healthcare burden and a significant market opportunity for innovative ophthalmology treatments.
The development strategy behind OLN324 focuses on targeting two biological pathways that contribute to the progression of these conditions.
VEGF plays an important role in the formation of new blood vessels and the regulation of vascular permeability. In retinal diseases such as wet AMD and DME, excessive VEGF activity can contribute to abnormal blood vessel growth and increased leakage, resulting in fluid accumulation and retinal damage.
Ang2 is another important regulator of vascular stability and inflammation. Increased Ang2 activity can contribute to the destabilization of blood vessels and may worsen vascular leakage and disease progression.
By targeting both VEGF and Ang2, OLN324 is designed to address complementary mechanisms involved in retinal vascular disease. This dual-targeting approach is intended to provide broader biological activity than therapies directed at a single pathway.
Ollin has reported encouraging proof-of-concept clinical findings demonstrating the potential of OLN324 to deliver improvements in retinal anatomy. These findings have supported the continued advancement of the candidate through clinical development.
However, additional clinical evaluation will be important to establish the therapy’s overall efficacy, safety profile and potential role in the treatment of wet AMD and diabetic macular edema.
Leadership Highlights Development Progress and Future Opportunities
Jason S. Ehrlich, MD, PhD, chief executive officer and co-founder of Ollin Biosciences, highlighted the company’s achievements since its establishment and expressed appreciation to the employees, co-founders and investors who contributed to the development of OLN324.
According to Ehrlich, Ollin was founded with a clear mission to develop innovative therapies capable of improving outcomes for patients with vision-threatening diseases. Over the past three years, the company has assembled a team focused on efficient execution and the advancement of promising ophthalmology treatments.
He emphasized that the rapid development of OLN324 and the generation of encouraging proof-of-concept data represent important accomplishments for the organization.
The clinical findings have demonstrated the candidate’s potential to produce more effective improvements in retinal anatomy, supporting the company’s continued efforts to advance the program.
Ehrlich also acknowledged the contributions of Ollin’s co-founders and colleagues, as well as the financial support provided by its investors. He expressed optimism about the next phase of development and the opportunity to continue advancing OLN324 following the completion of the proposed transaction.
The collaboration with Johnson & Johnson is expected to provide a broader platform for the program’s development. The company’s established capabilities in pharmaceutical research, clinical development and commercialization could support efforts to bring the investigational therapy closer to patients if it successfully completes clinical trials and receives the necessary regulatory approvals.
Investors and Strategic Partners Supported Ollin’s Development
Paul Berns, managing director at ARCH Venture Partners and co-founder and executive chairman of Ollin Biosciences, also discussed the strategic rationale behind the company’s establishment and its potential acquisition by Johnson & Johnson.
Berns noted that the worldwide retina therapeutics market represents an approximately $15 billion opportunity. He explained that Ollin was founded on the belief that combining an experienced team with sufficient financial resources could accelerate the acquisition and development of next-generation ophthalmology medicines.
The company’s strategy was designed to challenge established approaches in ophthalmology by identifying promising therapeutic candidates and providing them with the resources needed to advance through clinical development.
ARCH Venture Partners played an important role in establishing Ollin in 2023, working alongside its partners at Monograph Capital and Mubadala.
The initial formation of the company was supported by a strategic investment and development model intended to bring together the necessary expertise and funding to advance innovative therapies.
Earlier in 2026, Ollin expanded its investor base to support the late-stage clinical development of OLN324. The financing effort included support from TCGX, alongside a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds and institutional investors.
This expanded capital base was intended to provide the financial resources necessary to advance OLN324 through its later stages of development.
Berns expressed confidence that the potential acquisition by Johnson & Johnson could create an opportunity for OLN324 to reach a broader patient population. He also highlighted the importance of providing promising retinal therapies with the resources and development infrastructure needed to maximize their potential.
The proposed transaction therefore represents not only a significant corporate milestone for Ollin and its investors but also an opportunity to place the company’s lead investigational candidate within the development and commercialization capabilities of a major global pharmaceutical organization.
Johnson & Johnson Strengthens Its Position in Ophthalmology
The proposed acquisition provides Johnson & Johnson with access to a late-stage investigational ophthalmology asset targeting two major retinal diseases.
Ophthalmology continues to be an important area of pharmaceutical innovation, particularly as the global burden of age-related and diabetes-associated eye conditions increases. Wet AMD and diabetic macular edema are among the conditions that require ongoing medical attention because of their potential to cause substantial and permanent vision impairment.
The development of treatments capable of addressing multiple disease-related biological pathways has become an important focus in retinal therapeutics.
OLN324’s dual-targeting mechanism offers a differentiated development approach by simultaneously inhibiting VEGF and Ang2. If clinical studies confirm its therapeutic potential, the candidate could contribute to the development of additional treatment options for patients with these serious retinal conditions.
For Johnson & Johnson, the acquisition would add a Phase 3 investigational bispecific antibody to its ophthalmology pipeline. The company’s global resources and experience in pharmaceutical research and development could help support the continued clinical evaluation and potential commercialization of the candidate.
The transaction also reflects the broader biotechnology industry trend of established pharmaceutical companies acquiring clinical-stage companies with promising late-stage assets. Such acquisitions can provide smaller biotechnology organizations with access to larger development infrastructures while allowing pharmaceutical companies to expand their pipelines through external innovation.
The potential acquisition of Ollin is particularly significant because the company was founded only in 2023 and has rapidly advanced its lead program into Phase 3 development. This progress demonstrates the role of focused biotechnology companies and strategic investment partnerships in accelerating the development of next-generation medicines.
Transaction Details and Expected Closing Timeline
Under the terms of the definitive agreement, Johnson & Johnson will acquire Ollin Biosciences for $2.2 billion in upfront consideration. In addition, the transaction includes the potential for approximately $1.1 billion in regulatory and commercial milestone payments.
These additional payments will be contingent on the achievement of specified regulatory and commercial milestones. If all applicable milestones are achieved, the total potential value of the transaction could reach approximately $3.3 billion.
The closing of the acquisition is expected to take place by the end of 2026. Completion remains subject to applicable regulatory approvals and other customary closing conditions.
Until the transaction is completed, Ollin and Johnson & Johnson will continue to operate in accordance with the requirements applicable to the pending acquisition.
Goldman Sachs acted as the lead financial advisor to Ollin Biosciences, with Centerview Partners also serving as a financial advisor.
Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to Ollin for the transaction. Goodwin Procter LLP provided advice on corporate matters, while Morrison & Foerster LLP and Cooley LLP advised on intellectual property matters.
A Significant Development for Retinal Disease Research
The proposed acquisition of Ollin Biosciences by Johnson & Johnson represents an important milestone for the ophthalmology biotechnology sector. The transaction brings together Ollin’s focused development capabilities and its promising Phase 3 investigational candidate with the resources of a global pharmaceutical company.
At the center of the agreement is OLN324, a bispecific antibody designed to target VEGF and Ang2 for the treatment of wet AMD and diabetic macular edema. With more than 40 million people worldwide affected by these retinal diseases, the candidate is being developed to address a substantial unmet medical need.
Although further clinical studies and regulatory review will be necessary to determine its eventual clinical and commercial potential, the encouraging proof-of-concept findings and advancement into Phase 3 development represent important steps in the program’s progress.
If completed as expected, the acquisition could provide OLN324 with additional opportunities for development and potential commercialization, while strengthening Johnson & Johnson’s ophthalmology pipeline.
The anticipated closing by the end of 2026 will mark the next major step in the transaction, subject to regulatory approvals and customary closing requirements.
About Ollin Biosciences
Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology.


